AstraZeneca: Aspen Buys Remaining Rights to Anesthetic Portfolio

Date : 14/09/2017 @ 16:56
Source : Dow Jones News
Stock : Astrazeneca (AZN)
Quote : 34.45  -0.14 (-0.40%) @ 05:24
Astrazeneca share price Chart

AstraZeneca: Aspen Buys Remaining Rights to Anesthetic Portfolio

AstraZeneca (LSE:AZN)
Historical Stock Chart

1 Year : From Mar 2017 to Mar 2018

Click Here for more AstraZeneca Charts.

By Ian Walker


Pharmaceutical company AstraZeneca PLC (AZN.LN) said Thursday that Aspen Group's (APZ.AU) unit will buy the remaining rights to its anesthetic medicines for up to $766 million.

Following the initial deal entered into in June 2016--which saw Aspen Global Incorporated gain exclusive commercialization rights to the medicines in markets outside the U.S.--Aspen Global will now buy the remaining rights to Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.

It is paying an initial $555 million for the remaining rights to the intellectual property and manufacturing knowledge related to the anesthetic medicines, plus a further $211 million based on performance.

AstraZeneca said it will continue to manufacture and supply the medicines to Aspen Global during a transition period of up to five years.


Write to Ian Walker at; @IanWalk40289749


(END) Dow Jones Newswires

September 14, 2017 02:41 ET (06:41 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Your Recent History
Euro vs Au..
US Dollar ..
BHP Bilito..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:au D:20180319 18:39:19